Premium
Drug interactions between antihypertensive drugs and non‐steroidal anti‐inflammatory agents: a descriptive study using the French Pharmacovigilance database
Author(s) -
Fournier JeanPascal,
Sommet Agnès,
Durrieu Geneviève,
Poutrain JeanChristophe,
LapeyreMestre Maryse,
Montastruc JeanLouis
Publication year - 2014
Publication title -
fundamental and clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.655
H-Index - 73
eISSN - 1472-8206
pISSN - 0767-3981
DOI - 10.1111/fcp.12014
Subject(s) - pharmacovigilance , medicine , drug , pharmacology , antihypertensive drug , database , drug interaction , blood pressure , computer science
Drug–drug interactions ( DDI s) between antihypertensive drugs and non‐steroidal anti‐inflammatory drugs ( NSAID s) can lead to adverse drug reactions ( ADR s). Guidelines are available to help prescribers deal with these drug associations, but their implementation is not well evaluated. The aims of this study were to assess the prevalence of NSAID s exposure in patients treated with antihypertensive drugs, using the French Pharmacovigilance database, and explore the ADR s related to DDI s between antihypertensive drugs and NSAID s. Over the 11, 442 notifications of ADR s recorded in this database in patients treated with oral antihypertensive drugs between 2008 and 2010, 517 (4.5 and 95% CI : 4.1–4.9) also included exposure to NSAID s. These subjects were more frequently women, took more drugs in general, and were younger and less frequently treated with antiplatelet drugs. In 24.2% of them (125 patients), a DDI between NSAID s and antihypertensive drugs was potentially the cause of the reported ADR . Acute renal failure caused by DDI s between NSAID s and angiotensin‐converting enzyme inhibitors ( ACEI s), angiotensin receptor blockers ( ARB s), or diuretics was the most frequently reported ADR (20.7%). Finally, in the French Pharmacovigilance database, around one‐fourth of associations NSAID s + antihypertensive drugs are associated with a ‘serious’ ADR (mainly acute renal failure), suggesting that this well‐known DDI is not enough taken into account by prescribers.